glargine
- Generic Name
- glargine
Sanofi Aims to Expand Atopic Dermatitis Market Presence with Novel Therapies
• Sanofi's Dupixent achieved over $13 billion in global sales, establishing it as a gold standard in atopic dermatitis (AD) treatment.
• Sanofi is developing SAR444656 (KT-474), an IRAK4 degrader in Phase II trials, in collaboration with Kymera Therapeutics, with data expected in H1 2025.
• Amlitelimab, an anti-OX40L monoclonal antibody, is in Phase III trials, showing promise in reshaping the AD treatment landscape and increasing competition.
• Sanofi's strategic focus on innovation and pipeline development aims to maintain its competitive edge in the expanding atopic dermatitis market.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath